182. Viruses: Bedside to Bench
Saturday, October 22, 2011: 5:15 PM-6:45 PM
Room: 253ABC

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • apply knowledge of IL28B genetic data to clinical management of HCV
  • translate knowledge of the immune response to HCV and HIV into clinical care

Target Audience: Vaccinologists, Scientists, Researchers, Pharmacists, Microbiologists, Investigators, Infectious Diseases Physicians, Infectious Diseases Pediatricians, Fellows-in-Training, Clinicians, Academicians

Tracks: Investigative ID, HIV, Pediatric ID, Adult ID

Moderators:  Thomas Hawn, MD, PhD, University of Washington Medical Center and Joel Ernst, MD, FIDSA, New York University School of Medicine

CME Credits: Maximum of 1.5 hours of Category 1 credit possible

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of Pharmacy CE

ACPE Number: 0461-9999-11-125-L01-P


T. Hawn, None

J. Ernst, None

R. T. Chung, None

C. Rice, Apath, LLC: Shareholder, dividends
Genentech, Inc: Consultant, Consulting fee
GlaxoSmithKline: Scientific Advisor, Consulting fee
iTherX: Scientific Advisor, Consulting fee
Merck: Scientific Advisor, Consulting fee
Novartis Vaccines & Diagnostics: Scientific Advisor, Consulting fee
Vertex Pharmaceuticals: Consultant, Consulting fee

W. C. Greene, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.